In agreement with enhanced CD44 and CD133 expression in CEGBCs, their expression in glioblastoma stem cells correlates with cell proliferation, intra-tumor heterogeneity, invasion and poor prognosis in CD44-expressing glioma [46, 52]. The gene discussed is CD44; the disease is glioblastoma.